07/25/2018

Two years ago, federal drug authorities said they would consider licensing new suppliers of marijuana grown for scientific purposes, a move seen as an acknowledgment of the need for additional rigorous research into potential medical uses and risks of cannabis and its components. Hope you weren’t holding your breath. The Drug Enforcement Administration still has not granted additional licenses for a grow operation, despite receiving more than two dozen applications in the year after it announced it was open to approving one.

#Bioethics News: In its decision to approve two drugs for orange and grapefruit trees, the E.P.A. largely ignored objections from the C.D.C. and the F.D.A., which fear that expanding their use in cash crops could fuel antibiotic resistance in humans. https://t.co/9hAvsohLvB